BSXNYQHealthcare·Medical Devices#4 in industry

Boston Scientific Corporation

Reports in 86d· 2026-07-22

-36.1% · 90d

$59.95

-2.12 (-3.42%)

News

(2)

April 2026

Apr 22, 20266 days ago8-KHealthcare

Boston Scientific reports $5.2 billion in net sales, 11.6% growth

BSXBOSTON SCIENTIFIC CORP

# 📰 What This Document Is 📣 This document is a Current Report (Form 8-K) that serves as Boston Scientific's official announcement of its financial performance for the first quarter of 2026. Because it is an 8-K, it is designed to immediately inform investors and the public about key operational an

Read summaryView on SEC EDGAR

March 2026

Mar 30, 20260 months ago8-KHealthcare

BOSTON SCIENTIFIC CORP — 8-K Filing

BSXBOSTON SCIENTIFIC CORP

# 🧾 What This Document Is This is an SEC Form 8-K filing, which companies use to announce major news to investors. This specific filing contains two huge announcements from Boston Scientific, both released on the same day from a major medical conference. Think of it as a company pressing two "block

Read summaryView on SEC EDGAR

Key Data

Market Cap$89.10B

Open$61.21

Prev Close$62.07

Day Range$59.92 – $61.73

52W Range$59.39 – $109.50

Volume17,638,569

P/E (TTM)25.08

EPS$2.39

Dividend Yield—

Beta0.78

Profit Margin17.29%

Revenue Growth11.60%

Price Target$85.91(+43.3%)

Next Earnings2026-07-22(86d)

Analyst Ratings

Strong Buy33 analysts

Buy 32Hold 1Sell 0

About

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Healthcare · Medical Devices

59,000 employees

www.bostonscientific.com